» Articles » PMID: 38806989

MA Reader YTHDF1 Promotes Cardiac Fibrosis by Enhancing AXL Translation

Overview
Journal Front Med
Specialty General Medicine
Date 2024 May 28
PMID 38806989
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiac fibrosis caused by ventricular remodeling and dysfunction such as post-myocardial infarction (MI) can lead to heart failure. RNA N-methyladenosine (mA) methylation has been shown to play a pivotal role in the occurrence and development of many illnesses. In investigating the biological function of the mA reader YTHDF1 in cardiac fibrosis, adeno-associated virus 9 was used to knock down or overexpress the YTHDF1 gene in mouse hearts, and MI surgery in vivo and transforming growth factor-β (TGF-β)-activated cardiac fibroblasts in vitro were performed to establish fibrosis models. Our results demonstrated that silencing YTHDF1 in mouse hearts can significantly restore impaired cardiac function and attenuate myocardial fibrosis, whereas YTHDF1 overexpression could further enhance cardiac dysfunction and aggravate the occurrence of ventricular pathological remodeling and fibrotic development. Mechanistically, zinc finger BED-type containing 6 mediated the transcriptional function of the YTHDF1 gene promoter. YTHDF1 augmented AXL translation and activated the TGF-β-Smad2/3 signaling pathway, thereby aggravating the occurrence and development of cardiac dysfunction and myocardial fibrosis. Consistently, our data indicated that YTHDF1 was involved in activation, proliferation, and migration to participate in cardiac fibrosis in vitro. Our results revealed that YTHDF1 could serve as a potential therapeutic target for myocardial fibrosis.

Citing Articles

YTHDF3-mediated FLCN/cPLA2 axis improves cardiac fibrosis via suppressing lysosomal function.

Zhang Y, Diao H, Leng M, Wu Y, Huang B, Li X Acta Pharmacol Sin. 2025; .

PMID: 39806064 DOI: 10.1038/s41401-024-01425-2.

References
1.
Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M . Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2021; 27(2):625-643. PMC: 8898236. DOI: 10.1007/s10741-021-10105-w. View

2.
Bui A, Horwich T, Fonarow G . Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2010; 8(1):30-41. PMC: 3033496. DOI: 10.1038/nrcardio.2010.165. View

3.
Gonzalez A, Schelbert E, Diez J, Butler J . Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. J Am Coll Cardiol. 2018; 71(15):1696-1706. DOI: 10.1016/j.jacc.2018.02.021. View

4.
Azevedo P, Polegato B, Minicucci M, Paiva S, Zornoff L . Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. Arq Bras Cardiol. 2015; 106(1):62-9. PMC: 4728597. DOI: 10.5935/abc.20160005. View

5.
Burke R, Lighthouse J, Mickelsen D, Small E . Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts. Circ Heart Fail. 2019; 12(4):e005565. PMC: 6530564. DOI: 10.1161/CIRCHEARTFAILURE.118.005565. View